 |
Medication Safety Officers Society 3704 Members Strong A society of healthcare professionals dedicated to improving medication safety in healthcare organizations |
PLEASE NOTE: Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP).
Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org.
The 2016 NIOSH document on hazardous drugs lists Megace in Group 1. They further indicated that PPE is required for administration of agents in Group 1. If I am reading this correctly, oral liquid formulations require basically the same PPE as that required for the administration of IV Chemotherapy.
How are you translating this into practice? I would like to get rid of Megace completely, but my docs are not on board.
https://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list...